Table 1.

List of completed and ongoing clinical trials for the use of MSC in the treatment of ARDS

Trial ID	Title	Ref	Site	MSC source	No.of Pts	Route	Outcomes for MSC group
NCT01902082	Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome	[111]	China, Zhejiang	AT	6 Control 6 Exp	I.V	No adverse reactions. Modest clinical improvements
NCT02097641	Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)	[99]	USA, multi-centre	BM	20 Control 40 Exp	I.V	No adverse reactions. Modest clinical improvements
ChiCTR-OCC-15006355	Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment	[100]	China, Zhejiang	MB	44 Control 17 Exp	I.V	No adverse reactions. Reduction of Fatality rate
NCT02611609	A phase 1/2 study to assess MultiStem therapy in ARDS (MUST-ARDS)	[104]	USA, UK	BM-MAPC	9 Control 9 Exp 1 9 Exp 2 9 Exp 3	I.V	Preliminary: No adverse reactions. Reduction of Fatality rate. Reduction of ventilator assistance time
NCT02804945	Mesenchymal stem cells (MSCs) for treatment of ARDS (ARDS) in stem cell transplant patients		USA, Texas	BM	20 Exp	not stated	ongoing
NCT02215811	Treatment of severe acute respiratory distress syndrome with allogenic bone marrow derived MSCs		Sweden, Stockholm	BM	10 Exp	not stated	ongoing
NCT02444455	Human umbilical cord derived mesenchymal stem cell therapy in acute lung injury (UCMSC-ALI)		China, Beijing	UC	20 Exp	I.V	ongoing

AT adipose Tissue, BM bone marrow, MAPC multi adult progenitor cell, MB menstrual blood, I.V. intra venous, Exp experimental